Principal Financial Group Inc. Buys 5,829 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Principal Financial Group Inc. increased its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 6.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 89,961 shares of the specialty pharmaceutical company’s stock after purchasing an additional 5,829 shares during the quarter. Principal Financial Group Inc. owned 0.43% of ANI Pharmaceuticals worth $5,367,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. F M Investments LLC purchased a new stake in shares of ANI Pharmaceuticals in the third quarter valued at $3,686,000. James Investment Research Inc. bought a new stake in ANI Pharmaceuticals in the third quarter worth about $243,000. New York State Teachers Retirement System boosted its position in shares of ANI Pharmaceuticals by 1.7% during the third quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock valued at $1,439,000 after buying an additional 394 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of ANI Pharmaceuticals by 64.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 4,045 shares of the specialty pharmaceutical company’s stock valued at $241,000 after buying an additional 1,582 shares during the last quarter. Finally, State of Alaska Department of Revenue raised its holdings in shares of ANI Pharmaceuticals by 5.2% in the third quarter. State of Alaska Department of Revenue now owns 9,467 shares of the specialty pharmaceutical company’s stock worth $564,000 after buying an additional 464 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ANIP shares. Truist Financial upped their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. HC Wainwright reissued a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Raymond James increased their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Wednesday, September 18th. Piper Sandler assumed coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They set an “overweight” rating and a $68.00 price objective for the company. Finally, StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $77.33.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP opened at $55.10 on Thursday. ANI Pharmaceuticals, Inc. has a 12 month low of $48.20 and a 12 month high of $70.81. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -100.18 and a beta of 0.71. The company has a 50 day simple moving average of $58.35 and a two-hundred day simple moving average of $61.07.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. During the same period last year, the company earned $1.05 earnings per share. ANI Pharmaceuticals’s revenue for the quarter was up 12.5% compared to the same quarter last year. As a group, analysts predict that ANI Pharmaceuticals, Inc. will post 3.5 earnings per share for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.